• Jyoti Bala Chauhan
• Girish Chandran

Though the breast cancer deaths have been marginally reduced globally due to the diagnostic tools/ therapies, it is crucial to investigate the relative hazardous factors and methods to improve prognosis especially during chemotherapy. For many malignancies, serum tumor markers play an important role in patient management during initial diagnosis and in the course of chemotherapy. In breast cancer, however, the role of serum markers is less well established owing to limitation in such studies. The obvious dyslipidemia and lowered total plasma cholesterol among breast cancer patients, needs to be well studied for establishing the link between the plasma lipid profile and pathophysiology of the breast cancer.

Breast cancer, early markers, plasma lipid profile, total plasma cholesterol, chemotherapeutic hepatotoxicity

"Plasma levels of markers for therapeutic advances among breast cancer patients undergoing chemotherapy", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.6, Issue 5, page no.507-508, May-2019, Available :http://www.jetir.org/papers/JETIR1905N76.pdf

"Plasma levels of markers for therapeutic advances among breast cancer patients undergoing chemotherapy", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.6, Issue 5, page no. pp507-508, May-2019, Available at : http://www.jetir.org/papers/JETIR1905N76.pdf